trial

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

NCTId NCT02687984
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 44 (actual)
Sponsored by Indivior Inc.
Primary completion 2016-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
44 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2016-02
Primary completion
2016-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RBP-7000

Sponsors

Indivior Inc.Lead Sponsor

Sites

2 total
Garden Grove, United StatesTorrance, United States

Facts & assertions

4 sourced
Enrollment
44
Phase
PHASE1
Primary Completion Date
2016-05
Status
COMPLETED
relationships
The graph out of here
drug
RBP-7000
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication